Compare OCFC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | SDGR |
|---|---|---|
| Founded | 1902 | 1990 |
| Country | United States | United States |
| Employees | 1007 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 925.8M |
| IPO Year | N/A | 2020 |
| Metric | OCFC | SDGR |
|---|---|---|
| Price | $18.15 | $15.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $21.67 | $21.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $47.51 | $0.76 |
| Revenue Next Year | $21.97 | $4.60 |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $16.09 | $10.95 |
| 52 Week High | $20.61 | $23.75 |
| Indicator | OCFC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 61.45 |
| Support Level | $17.29 | $11.27 |
| Resistance Level | $18.62 | $16.47 |
| Average True Range (ATR) | 0.44 | 0.89 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 55.93 | 59.14 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.